ReviewThe EMBO journal2015
Autophagy in malignant transformation and cancer progression.
Review in The EMBO journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 713 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
713 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,149 citations in OpenAlex.
- The dual role of autophagy in HPV-positive head and neck squamous cell carcinoma: a systematic review.Journal of cancer research and clinical oncology · 2024Pooled it
- Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.Annals of medicine · 2021Pooled it
- Autophagy modulation in cancer.Nature reviews. Drug discovery · 2026Review
- Autophagy in Melanoma: Molecular Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Overcoming IGF1R-mediated resistance to oncolytic HSV1 and radiotherapy via triple combination therapy.Cell death & disease · 2026Article
- Emerging New Pathways in Malignant Neoplasms and Neurodegenerative Disorders: Perspectives for Therapeutics.Cells · 2026Review
- Transcriptional and epigenetic regulation of autophagy: mechanisms, disease relevance and therapeutic opportunities.Signal transduction and targeted therapy · 2026Review
- The nuclear shredder behind PARPi resistance.Nature cell biology · 2026Article
- CREB-SEC61G feedback loop sustains enhanced autophagy and boosts proliferation in PDAC.Cell death & disease · 2026Article
- Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization.Molecular oncology · 2026Article
- OTUB2-mediated deubiquitination upregulates U2AF2 to promote colorectal cancer evasion of autophagy-ferroptosis.Cell death & disease · 2026Article
- YAP inactivation-mediated autophagy inhibition contributes to cisplatin resistance in ovarian cancer cells.Journal of ovarian research · 2026Article
- Targeting Autophagy to Overcome Chemoresistance and Immune Resistance in Triple-Negative Breast Cancer.Cancers · 2026Review
- Ubiquitin ligase RCHY1 regulates autophagosome-lysosome fusion.Cell death discovery · 2026Article
- Significance of amino acid recycling from vacuoles for viability and sporulation of yeast cells under starvation conditions.Scientific reports · 2026Article
- MOV10, a novel immunotherapy and prognostic biomarker, contributes to glioma development by regulating autophagy.Scientific reports · 2026Article
- Article
- Tumor metabolic plasticity in therapy resistance: from the Warburg effect to mitochondrial hijacking.Theranostics · 2026Review
- Unraveling autophagy-metabolism crosstalk in cancer: Molecular insights and therapeutic strategies.Theranostics · 2026Review
- Natural Combatants: How Herbal Monomers Regulate Autophagy in Ovarian Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
653 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 20 institutions in 11 countries.
Funding
Abstract
Autophagy plays a key role in the maintenance of cellular homeostasis. In healthy cells, such a homeostatic activity constitutes a robust barrier against malignant transformation. Accordingly, many oncoproteins inhibit, and several oncosuppressor proteins promote, autophagy. Moreover, autophagy is required for optimal anticancer immunosurveillance. In neoplastic cells, however, autophagic responses constitute a means to cope with intracellular and environmental stress, thus favoring tumor progression. This implies that at least in some cases, oncogenesis proceeds along with a temporary inhibition of autophagy or a gain of molecular functions that antagonize its oncosuppressive activity. Here, we discuss the differential impact of autophagy on distinct phases of tumorigenesis and the implications of this concept for the use of autophagy modulators in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.